| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.93▲ | 3.94▼ | 3.94▼ | 3.89▲ | 4.06▼ |
| MA10 | 3.93▲ | 3.93▲ | 3.92▲ | 3.86▲ | 3.75▲ |
| MA20 | 3.94▼ | 3.93▲ | 3.97▼ | 3.95▼ | 3.43▲ |
| MA50 | 3.94▼ | 3.84▲ | 3.82▲ | 3.71▲ | 3.16▲ |
| MA100 | 3.96▼ | 3.83▲ | 3.93▲ | 3.29▲ | N/A |
| MA200 | 3.77▲ | 3.95▼ | 3.78▲ | 2.88▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | -0.005▼ | -0.006▼ | -0.013▼ | 0.101▲ |
| RSI | 50.059▲ | 52.197▲ | 54.357▲ | 53.340▲ | 55.206▲ |
| STOCH | 62.987 | 54.035 | 34.127 | 53.380 | 62.202 |
| WILL %R | -18.182▲ | -45.833 | -69.048 | -51.681 | -52.206 |
| CCI | 60.172 | -37.333 | -51.852 | 2.196 | 42.926 |
|
Friday, September 19, 2025 11:44 AM
On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the ...
|
|
Friday, September 19, 2025 11:19 AM
Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.
|
|
Friday, September 19, 2025 04:25 AM
This Phase 1b study was previously conducted by Bird Rock Bio, Inc., which Skye acquired in 2023.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/10/25 | 3.93 | 3.94 | 3.89 | 3.935 | 61,443 |
| 30/09/25 | 4.03 | 4.11 | 3.86 | 3.93 | 289,986 |
| 29/09/25 | 4.13 | 4.15 | 3.86 | 3.88 | 373,896 |
| 26/09/25 | 3.60 | 4.16 | 3.505 | 4.11 | 772,100 |
| 25/09/25 | 3.56 | 3.61 | 3.36 | 3.60 | 288,800 |
| 24/09/25 | 3.75 | 3.77 | 3.512 | 3.58 | 343,700 |
| 23/09/25 | 3.96 | 3.96 | 3.65 | 3.69 | 382,300 |
| 22/09/25 | 4.06 | 4.10 | 3.85 | 3.89 | 418,000 |
| 19/09/25 | 3.94 | 4.05 | 3.868 | 4.00 | 313,600 |
| 18/09/25 | 3.99 | 4.19 | 3.85 | 3.94 | 294,700 |
|
|
||||
|
|
||||
|
|